Thymogen

clinical trials

Also known as: Glutamyl-Tryptophan, Glutoxim analog

**Mechanism of Action** Thymogen (glutamyl-tryptophan) is a synthetic dipeptide immunomodulator that exerts its effects primarily through modulation of T-cell differentiation and function. It binds to specific receptors on thymic epithelial cells and lymphocytes, enhancing the production of thymic hormones and cytokines such as interleukin-2 (IL-2) and interferon-gamma (IFN-γ). This restores the balance between T-helper (Th1/Th2) responses, promotes maturation of T-cell precursors, and improves antigen-presenting cell activity. The compound also exhibits antioxidant properties by reducing oxidative stress in immune cells, which contributes to its protective effects during infection and immunodeficiency. **Key Research Findings** Clinical trials (88 PubMed references) demonstrate Thymogen’s efficacy in reducing the duration and severity of recurrent respiratory infections, herpesvirus reactivation, and postoperative immune suppression. In HIV-associated immunodeficiency, it increases CD4+ T-cell counts and reduces viral load when combined with antiretroviral therapy. Animal studies show enhanced survival in sepsis models via attenuation of pro-inflammatory cytokine storms. Notably, its dipeptide structure allows oral and parenteral administration with minimal toxicity, though bioavailability data remain limited. **Clinical Relevance** Thymogen is approved in Eastern Europe for adjunctive treatment of secondary immunodeficiencies, chronic infections, and cancer-related immune dysfunction. It is contraindicated in autoimmune diseases due to potential exacerbation of Th1-mediated responses. Current research focuses on optimizing dosing regimens for pediatric and geriatric populations. While promising, its use outside Eastern Europe remains investigational, and larger randomized trials are needed to confirm efficacy against placebo. For research purposes only — not medical advice.

Key data

Category
Immune Modulation
Molecular weight
333.34 g/mol
Molecular formula
C16H19N3O5
CAS number
38101-59-6
Administration
intranasal, intramuscular
Research status
clinical trials
References
88
Tags
thymic, dipeptide, immunostimulant

Research & studies

Hepatoprotective Effects of Thymogen Analogues in Hydrazine Hepatopathy in Rats
Bulletin of experimental biology and medicine · 2025 · PubMed

Hydrazine injection decreased catalase activity and increased MDA concentration.; Lower doses of peptides inhibited lipid peroxidation and stimulated hepatocyte regeneration.; Thymogen analogue with D-Ala at the C-terminus was the most effective.; Higher doses of thymogen and analogues did not further improve hepatoprotective activity.

The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples
International journal of molecular sciences · 2024 · PubMed

Thymogen (L-Glu-L-Trp) acts as an immunostimulant, while Thymodepressin (D-Glu-D-Trp) acts as an immunosuppressor.; These enantiomeric drugs demonstrate up-and-down homeostasis regulation, showing reciprocal biological activities.; Manipulating chirality offers a strategy to enhance peptide resistance to proteolysis and improve biomolecular interactions.; The study suggests removing the chiral wall between L- and D-biomolecules for therapeutic development.

Reparative and Antioxidant Effects of New Analogues of Immunomodulator Thymogen in Experimental Model of Liver Damage
Bulletin of experimental biology and medicine · 2023 · PubMed

Carbon tetrachloride caused fat degeneration, decreased catalase, and increased malondialdehyde.; Peptides suppressed oxidative peroxidation and stimulated reparative regeneration.; Thymogen analogues showed stronger hepatotropic and antioxidant effects than Thymogen.; Adding D-Ala to the C-end of Thymogen yielded the highest efficiency.

[Endoscopic and morphometric analysis of the reduction of acute inflammatory process in the gastric mucosa after therapy with Regasthym Gastro]
Terapevticheskii arkhiv · 2023 · PubMed
[Repair stimulator alpha-glutamyl-tryptophan in the complex therapy of chronic atrophic gastritis: results of histological examination]
Arkhiv patologii · 2023 · PubMed

Significant 26.1% increase in gastric mucosal gland count per mm² with alpha-glutamyl-tryptophan vs baseline and placebo.; Tendency toward decreased signs of intestinal metaplasia in the treatment group.; No significant change in CXCL-12 expression in the treatment group, but placebo showed increased expression.; Significant increase in CDX-2 expression in the treatment group, suggesting improved repair mechanisms.

The Effect of Drugs with α-Glutamyl-Tryptophan for Cytokine Secretion and Level of Surface Molecule ICAM-1 In Vitro
Cell and tissue biology · 2023 · PubMed

α-Glu-Trp reduced TNF-induced IL-1 production and increased TNF-stimulated ICAM-1 on endothelial cells.; α-Glu-Trp decreased TNF-induced IL-8 secretion and increased spontaneous ICAM-1 in mononuclear cells.; Cytovir-3 increased spontaneous IL-8 secretion by both endothelial and mononuclear cells.; Cytovir-3 elevated TNF-induced ICAM-1 on endothelial cells and spontaneous ICAM-1 on mononuclear cells.

Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
International journal of molecular sciences · 2022 · PubMed

All five peptides increased tyrosine phosphorylation of mitogen-activated cytoplasmic kinases, modulating proliferative patterns.; Chonluten tripeptide inhibited TNF production in monocytes exposed to LPS, linked to TNF tolerance.; All peptides inhibited LPS-stimulated expression of TNF and pro-inflammatory IL-6 in terminally differentiated THP-1 cells.; Peptide-treated THP-1 cells showed reduced adhesion to activated endothelial cells, indicating anti-inflammatory effects.

Synthetic and natural immunomodulators acting as interferon inducers
Current pharmaceutical design · 2009 · PubMed

Interferon inducers are less known in the Western world but have a substantial market share in former socialist republics.; The review covers over 20 interferon inducers, such as Arbidol, Cycloferon, and Neovir.; These inducers have been used for the same clinical indications as natural and recombinant interferons.; The pharmaceutical industry behind the 'iron curtain' offers a variety of these agents for potential global use.

Frequently asked questions

What is Thymogen?

**Mechanism of Action** Thymogen (glutamyl-tryptophan) is a synthetic dipeptide immunomodulator that exerts its effects primarily through modulation of T-cell differentiation and function. It binds to specific receptors on thymic epithelial cells and lymphocytes, enhancing the production of thymic hormones and cytokine

How does Thymogen work?

Synthetic dipeptide (Glu-Trp) immunomodulator used in Eastern Europe to restore immune balance during infection and immunodeficiency.

What is the research status of Thymogen?

Thymogen is currently classified as clinical trials, with 88 research references on record. This is for research purposes only and is not medical advice.

What is the molecular weight of Thymogen?

Thymogen has a molecular weight of approximately 333.34 g/mol (formula C16H19N3O5).

Related peptides

Build on Thymogen data programmatically

Structured peptide data, semantic search, and AI summaries via one API.

Get a free API key